RESPIRATORY SYNCYTIAL VIRUS (RSV)

This large Phase 3 study is testing an experimental RSV vaccine in 25,000 adults aged 60 and older. The goal is to see if a single shot can prevent lower respiratory tract disease caused by RSV, a common virus that can be dangerous for seniors. Participants will receive either th…

This early-stage trial is testing several new vaccine formulas against two viruses: RSV (a common cause of lung infections) and H5N1 bird flu. About 570 healthy adults aged 18 to 49 will receive one of the vaccines. The main goal is to check safety and see how well the vaccines t…

This study looks at how well the RSV vaccine Arexvy works in 170 adults with weakened immune systems. Participants will receive up to 3 vaccine doses over a year and be monitored for side effects and immune response. The goal is to find the best dosing schedule to protect this hi…

This study tests an RSV vaccine in adults aged 18-59 who have health conditions like chronic lung, heart, or kidney disease that put them at higher risk for severe RSV. The goal is to see if the vaccine triggers a strong immune response and is safe. Participants receive one shot …

This early-stage trial is testing an experimental drug called SIBP-A16 in 140 healthy adults aged 18 to 45. The goal is to see if it is safe and how the body handles it. Participants receive a single injection of the drug, a placebo, or an existing RSV antibody. The study does no…

This study checks the safety of a monthly injection called palivizumab in infants and children under 24 months who are at high risk for severe RSV disease. About 138 participants will receive up to 5 injections over the study period. The goal is to see how safe the drug is and tr…

This study will test 10,000 people in Cambodia for antibodies against 57 different infectious diseases, including dengue, flu, and malaria. The goal is to learn how these diseases spread in communities and which ones are most common. This information will help health officials de…